Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last?

Keros Therapeutics, Inc. (KROS) shares ended the last trading session 9.8% higher at $15.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.1% loss over the past four weeks.The stock price gain can be attributed to investor optimism regarding the potential of Keros’ pipeline candidate, KER-065, being developed for treating neuromuscular disorders, with an initial focus on Duchenne muscular dystrophy in a phase I study. Its most advanced product candidate, elritercept, is being developed in partnership with Takeda to treat cytopenias, such as anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis.This company is expected to post quarterly loss of $1.11 per share in its upcoming report, which represents a year-over-year change of +21.3%. Revenues are expected to be $7.67 million, up 1865.6% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For Keros Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KROS going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Keros Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Illumina (ILMN), closed the last trading session 4.2% higher at $99.5. Over the past month, ILMN has returned -7.1%.For Illumina, the consensus EPS estimate for the upcoming report has changed +0.7% over the past month to $1.17. This represents a change of +2.6% from what the company reported a year ago. Illumina currently has a Zacks Rank of #3 (Hold).5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Keros Therapeutics, Inc. (KROS): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks